Summary
Intensive interest and passion have been generated in the search for orally effective inotropes over the past few decades. Several extensive clinical evaluations of these agents have now been completed. Both β-adrenergic agonists and phosphodiesterase inhibitors that exert cardiotonic action by increasing intracellular cyclic adenosine monophosphate produced dramatic short-term hemodynamic benefits in patients with advanced heart failure. However, patients who received long-term treatment with these agents had unfavorable outcomes, including a higher mortality and morbidity rate, and deleterious side effects. The principal mechanisms responsible for the limitations in its usefulness in long-term therapy may be related to increased energy expenditure and potential arrhythmogenic effects. In contrast to these pessimistic views, one quinolinone derivative has been shown to exert a positive inotropic action without a chronotropic effect. Patients with mild heart failure responded favorably to this agent in long-term therapy. The lack of an increase in heart rate might be the cause of this salutary effect. Concerns regarding the possible improvement in the prognosis of patients with heart failure due to the use of positive inotropic therapy still continue.
Similar content being viewed by others
References
Massie B, Bourassa M, DiBianco R, et al. for the Amrinone Multicenter Trial Group. Long-term oral administration of amrinone for congestive heart failure: Lack of efficacy in a multicenter controlled trial. Circulation 1985;71:963–971.
Petein M, Levine B, Cohn JN. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure. Circulation 1986;73(Suppl III):III230-III236.
Uretsky BF, Jessup M, Konstam MA, et al. for the Enoximone Multicenter Trial Group. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Circulation 1990;82:774–780
Dies F, Knell MJ, Whitlow P, et al. Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 1986;74(Suppl II):II38.
Lambertz H, Meyer J. Erbel R. Long-term hemodynamic effects of prenalterol in patients with severe congestive heart failure. Circulation 1984;69:298–305.
The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet 1990;336:1–6.
Katz AM. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 1986; 73(Suppl III):III184-III190.
OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 1990;4:419–426.
Feldman AM, Baubhman KL, Lee WK, et al. Randomized double-blind placebo trial of OPC-8212 in patients with heart failure; morbidity/mortality in 80 patients. Circulation 1989;80(Suppl):II176.
Feldman MD, Gwathmey JK, Phillips P, et al. Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol 1988;3:273–283.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sasayama, S. What do the newer inotropic drugs have to offer?. Cardiovasc Drug Ther 6, 15–18 (1992). https://doi.org/10.1007/BF00050911
Issue Date:
DOI: https://doi.org/10.1007/BF00050911